About: Efficacy and safety of 2-hour urokinase regime in acute pulmonary embolism: a randomized controlled trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Efficacy and safety of 2-hour urokinase regime in acute pulmonary embolism: a randomized controlled trial Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Efficacy and safety of 2-hour urokinase regime in acute pulmonary embolism: a randomized controlled trial
Creator	Wang, Chen Cheng, Xiansheng Cheng, Zhaozhong Dai, Huaping Huang, Kewu Liang, Lirong Lu, Weixuan Yang, Yuanhua Yuan, Yadong Zhai, Zhenguo Zhang, Zhonghe Shen, Ying
Source	Medline; PMC
abstract	BACKGROUNDS: Urokinase (UK) 2 200 U/kg·h for 12 hours infusion(UK-12 h)is an ACCP recommended regimen in treating acute pulmonary embolism (PE). It is unclear whether this dose and time can be reduced further. We compared the efficacy and safety of 20, 000 U/kg for 2 hours (UK-2 h) with the UK-12 h regime in selected PE patients. METHODS: A randomized trial involving 129 patients was conducted. Patients with acute PE were randomly assigned to receive either UK-12 h (n = 70), or UK-2 h (n = 59). The efficacy was determined by the improvement of right heart dysfunction and perfusion defect at 24 h and 14 d post UK treatment. The bleeding incidence, death rate and PE recurrence were also evaluated. RESULTS: Similarly significant improvements in right heart dysfunction and lung perfusion defects were observed in both groups. Overall bleeding incidents were low in both groups. Major bleeding directly associated with UK infusion occurred in one patient in the UK-2 h group and one in the UK-12 h group. Mortality rates were low, with one reported fatal recurrent in the UK-12 h group and none in the UK-2 h group. When the rate of bleeding, death and PE recurrence were compared separately in the hemodynamic instability and the massive anatomic obstruction subgroups, no significant difference was found. CONCLUSIONS: The UK-2 h regimen exhibits similar efficacy and safety as the UK-12 h regimen for acute PE. TRIAL REGISTRATION: Clinical trial registered with http://clinicaltrials.gov/ct2/show/NCT00799968 (Identifier: NCT 00799968)
has issue date	2009-12-29(xsd:dateTime)
bibo:doi	10.1186/1465-9921-10-128
bibo:pmid	20040086
has license	cc-by
sha1sum (hex)	87a937ec2cd698b7d24ade1803a22852747ec8c7
schema:url	https://doi.org/10.1186/1465-9921-10-128
resource representing a document's title	Efficacy and safety of 2-hour urokinase regime in acute pulmonary embolism: a randomized controlled trial
has PubMed Central identifier	PMC2806365
has PubMed identifier	20040086
schema:publication	Respir Res
resource representing a document's body	covid:87a937ec2cd698b7d24ade1803a22852747ec8c7#body_text
is schema:about of	named entity 'UROKINASE' named entity 'DOSE' named entity '12 HOURS' named entity 'RESEARCH' named entity 'Urokinase' covid:arg/87a937ec2cd698b7d24ade1803a22852747ec8c7 named entity 'ACUTE PULMONARY EMBOLISM' named entity 'REGIMEN' named entity 'SELECTED' named entity 'COMPARED' named entity 'PATIENTS' named entity 'SAFETY' named entity 'EFFICACY' named entity 'RECOMMENDED' named entity 'REGIME' named entity 'REDUCED' named entity '20%' named entity 'HOUR' named entity 'RANDOMIZED CONTROLLED TRIAL' named entity 'RESPIRATORY' named entity 'REGIME' named entity 'SAFETY' named entity 'UROKINASE' named entity 'ACUTE PULMONARY EMBOLISM' named entity '200' named entity 'UNCLEAR' named entity 'TREATING' named entity 'EFFICACY' named entity '2 HOURS' named entity 'TIME' named entity 'B7H' named entity 'INFUSION' named entity 'patients' named entity 'embolism' named entity 'randomized controlled trial' named entity 'BUN' named entity 'intracranial hemorrhage' named entity 'level of significance' named entity 'pulmonary artery pressure' named entity 'major bleeding' named entity 'kidney' named entity 'sample size' named entity 'mortality rate' named entity 'allergic reaction' named entity 'death rates' named entity 'intravenous infusion' named entity 'thrombolytic' named entity 'Lung' named entity 'thrombolytic therapy' named entity 'left ventricular' named entity 'V/Q scan' named entity 'clinical research' named entity 'prognosis' named entity 'international normalized ratio' named entity 'Pulmonary EmbolIsm' named entity 'infusion' named entity 'pulmonary hypertension' named entity 'Echocardiogram' named entity 'SPAP' named entity 'pulmonary artery' named entity 'CTPA' named entity 'SPAP' named entity 'cardiogenic shock' named entity 'mortality rates' named entity 'perfusion' named entity 'pulmonary circulation' named entity 'LMWH' named entity 'perfusion' named entity 'infor' named entity 'developing countries'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software